These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 39189472)

  • 41. Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection.
    Yabusaki N; Fujii T; Yamada S; Suzuki K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Int J Surg; 2016 Jun; 30():136-42. PubMed ID: 27154615
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.
    Aslan V; Kılıç ACK; Sütcüoğlu O; Eraslan E; Bayrak A; Öksüzoğlu B; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
    Urol Oncol; 2022 Nov; 40(11):494.e1-494.e10. PubMed ID: 36137881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Sarcopenia on the Prognosis of Clinical Outcomes in Patients With Hepatocellular Carcinoma After Hepatic Resection.
    Polvieng T; Hongjinda S; Thienhiran A; Burasakarn P; Fuengfoo P
    Am Surg; 2024 Jun; 90(6):1447-1455. PubMed ID: 38516765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of magnetic resonance imaging-derived sarcopenia with outcomes of patients with hepatocellular carcinoma after hepatectomy.
    Rao C; Chen J; Xu K; Xue C; Wu L; Huang X; Chen S; Rao S; Li F
    Abdom Radiol (NY); 2024 Jul; 49(7):2272-2284. PubMed ID: 38900325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.
    Lanza E; Masetti C; Messana G; Muglia R; Pugliese N; Ceriani R; Lleo de Nalda A; Rimassa L; Torzilli G; Poretti D; D'Antuono F; Politi LS; Pedicini V; Aghemo A;
    PLoS One; 2020; 15(6):e0232371. PubMed ID: 32555707
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors.
    Zhang L; Ma W; Qiu Z; Kuang T; Wang K; Hu B; Wang W
    Front Immunol; 2023; 14():1219929. PubMed ID: 37545502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
    Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J
    Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.
    Deng GM; Song HB; Du ZZ; Xue YW; Song HJ; Li YZ
    World J Gastroenterol; 2024 Feb; 30(8):863-880. PubMed ID: 38516238
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma.
    Yang JF; Huang WY; Lo CH; Lee MS; Lin CS; Shen PC; Dai YH; Wang YF; Chen TW
    Sci Rep; 2022 Nov; 12(1):19100. PubMed ID: 36352042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis.
    Deng HY; Chen ZJ; Qiu XM; Zhu DX; Tang XJ; Zhou Q
    Nutrition; 2021 Oct; 90():111345. PubMed ID: 34166897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Feng J; Zhao Y; Zhai L; Zhou J
    Medicine (Baltimore); 2024 May; 103(18):e38037. PubMed ID: 38701263
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
    Chan SL; Ryoo BY; Mo F; Chan LL; Cheon J; Li L; Wong KH; Yim N; Kim H; Yoo C
    J Hepatol; 2024 Aug; 81(2):258-264. PubMed ID: 38570034
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.
    Pinato DJ; Marron TU; Mishra-Kalyani PS; Gong Y; Wei G; Szafron D; Sharon E; Saeed A; Jun T; Dharmapuri S; Naqash AR; Peeraphatdit T; Gampa A; Wang Y; Khan U; Muzaffar M; Navaid M; Lee CJ; Lee PC; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Hildebrand H; Abugabal YI; Pressiani T; Personeni N; D'Alessio A; Kaseb AO; Huang YH; Ang C; Schneider J; Pillai A; Rimassa L; Goldberg KB; Pazdur R; Theoret M; Lemery S; Fashoyin-Aje '; Cortellini A; Pelosof L
    Eur J Cancer; 2021 Nov; 157():140-152. PubMed ID: 34508996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
    Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.